ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 19, 2024

Primary Completion Date

December 31, 2027

Study Completion Date

June 30, 2028

Conditions
Recurrent OligodendrogliomaProgressive Oligodendroglioma
Interventions
BIOLOGICAL

TTRNA-DC vaccines with GM-CSF

Participants will receive up to 9 intradermal DC vaccines (three -bi-weekly (q2 weeks) for priming, monthly for additional 2-3 cycles during T cell expansion, and three bi-weekly during T cell engraftment

BIOLOGICAL

Autologous Hematopoietic Stem cells (HSCs)

Participants will receive a single infusion of autologous CD34+ HSCs

BIOLOGICAL

TTRNA-xALT

Participants will receive a single infusion of ex vivo expanded tumor-reactive T cells

DRUG

Td vaccine

All patients will receive a full Td booster IM vaccine 4-24 hours prior to Vaccine #1 and vaccine site pretreatment with a one-fifth dose of Td intradermally, at the site of planned vaccine, 4-24 hours prior to vaccines #3, #5, #7 and #9.

Trial Locations (1)

32610

University of Florida Health Shands Hospital, Gainesville

All Listed Sponsors
collaborator

Oligo Nation, Inc

UNKNOWN

lead

University of Florida

OTHER

NCT06254326 - ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients | Biotech Hunter | Biotech Hunter